DeepMed Research

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Real-world, Prospective Observational Study of Rimegepant ODT for the Acute Treatment of Migraine Attacks in Adults.

Completed

Conditions: Migraine

First Posted Date: 2024-06-21

Last Posted Date: 2025-03-30

Lead Sponsor: Pfizer

Target Recruit Count: 342

Registration Number: NCT06467370

Locations: 🇺🇸
Pfizer, New York, New York, United States

A Study to Learn How Different Forms of The Study Medicine Called Phenytoin Are Taken up Into the Blood in Healthy Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Phenytoin (Ascoli)
Drug: Phenytoin (Vega Baja)

First Posted Date: 2024-06-20

Last Posted Date: 2024-10-08

Lead Sponsor: Pfizer

Target Recruit Count: 35

Registration Number: NCT06466473

Locations: 🇺🇸
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut, United States

A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause

Phase 2

Recruiting

Conditions: Breast Cancer

Interventions: Drug: PF-07220060
Drug: letrozole

First Posted Date: 2024-06-18

Last Posted Date: 2024-11-19

Lead Sponsor: Pfizer

Target Recruit Count: 118

Registration Number: NCT06465368

Locations: 🇨🇳
Mackay Memorial Hospital, Taipei, Taiwan
🇨🇳
Chang Gung Medical Foundation-Linkou Branch, Taoyuan, Taiwan
🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

and more 25 locations

Description of Relugolix Use in Patients With Prostate Cancer Within the VHA

Completed

Conditions: Prostate Cancer

Interventions: Drug: Relugolix

First Posted Date: 2024-06-17

Last Posted Date: 2025-02-17

Lead Sponsor: Pfizer

Target Recruit Count: 500

Registration Number: NCT06462014

Locations: 🇺🇸
Pfizer, New York, New York, United States

A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)

Phase 2

Recruiting

Conditions: Gram-negative Bacterial Infection

First Posted Date: 2024-06-17

Last Posted Date: 2025-05-20

Lead Sponsor: Pfizer

Target Recruit Count: 48

Registration Number: NCT06462235

Locations: 🇺🇸
Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, United States
🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸
Norton Children's Hospital, Louisville, Kentucky, United States

and more 16 locations

A Study to Learn How the Study Medicine Called Zavegepant is Taken Up Into Blood and Breast Milk of Healthy Breast-Feeding Women

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Zavegepant 10mg

First Posted Date: 2024-06-11

Last Posted Date: 2024-10-08

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT06453356

Locations: 🇺🇸
Bio-Kinetic Clinical Applications, LLC dba QPS-MO, Springfield, Missouri, United States
🇺🇸
Bio-Kinetic Clinicals Applications LLC DBA QPS-MO Patient Screening and Recruitment Center Center), Springfield, Missouri, United States

A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination

Phase 1

Terminated

Conditions: Advanced or Metastatic Solid Tumors
Colorectal Cancer
Non-Small Cell Lung Cancer
Urothelial Cancer
Melanoma

Interventions: Biological: PF-07329640
Biological: bevacizumab
Biological: sasanlimab

First Posted Date: 2024-06-07

Last Posted Date: 2024-11-06

Lead Sponsor: Pfizer

Target Recruit Count: 4

Registration Number: NCT06448364

Locations: 🇵🇷
Hospital Oncológico Dr. Isaac González-Martinez, Rio Piedras, Puerto Rico
🇺🇸
NEXT Oncology, San Antonio, Texas, United States
🇵🇷
Pan American Center for Oncology Trials, LLC, Rio Piedras, Puerto Rico

and more 3 locations

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Phase 1

Recruiting

Conditions: Carcinoma, Non-Small-Cell Lung
Carcinoma, Pancreatic Ductal
Colorectal Neoplasms

Interventions: Drug: PF-07934040
Combination Product: Gemcitabine
Combination Product: Cetuximab
Combination Product: Fluorouracil
Combination Product: Pembrolizumab
Combination Product: Nab-paclitaxel
Combination Product: Oxaliplatin
Combination Product: pemetrexed
Combination Product: Leucovorin
Combination Product: Cisplatin
Combination Product: Bevacizumab
Combination Product: Paclitaxel
Combination Product: Carboplatin

First Posted Date: 2024-06-07

Last Posted Date: 2025-05-13

Lead Sponsor: Pfizer

Target Recruit Count: 330

Registration Number: NCT06447662

Locations: 🇺🇸
University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP), Aurora, Colorado, United States
🇺🇸
Highlands Oncology Group, PA, Rogers, Arkansas, United States
🇺🇸
City of Hope Investigational Drug Service (IDS), Duarte, California, United States

and more 20 locations

A Study About Modified RNA Vaccines Against Influenza in Healthy Adults

Phase 2

Completed

Conditions: Influenza, Human

Interventions: Biological: Influenza ModRNA Vaccine
Biological: Quadrivalent Influenza Vaccine (QIV)

First Posted Date: 2024-05-31

Last Posted Date: 2025-02-14

Lead Sponsor: Pfizer

Target Recruit Count: 1202

Registration Number: NCT06436703

Locations: 🇺🇸
Clinical Research Professionals, Chesterfield, Missouri, United States
🇺🇸
Artemis Institute for Clinical Research, San Diego, California, United States
🇺🇸
Duke Vaccine and Trials Unit, Durham, North Carolina, United States

and more 26 locations

A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: tofacitinib
Drug: tumor necrosis factor inhibitors (TNFi)
Drug: abatacept
Drug: tocilizumab or sarilumab

First Posted Date: 2024-05-17

Last Posted Date: 2025-01-22

Lead Sponsor: Pfizer

Target Recruit Count: 21340

Registration Number: NCT06418529

Locations: 🇺🇸
Pfizer, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy